Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 19, 2006

GSK Procures 1,000 Illumina BeadChips for Whole-Genome Association Studies

  • GlaxoSmithKline (GSK) purchased 1,000 HumanHap550 BeadChips from Illumina. The agreement also includes the addition of a statement of work to utilize Illumina’s Fast-Track Genotyping Service to process approximately 4,000 disease samples for pharmacogenetics application.

    By the end of 2006, Illumina will have genotyped more than 15,000 samples and reported nearly 3.5 billion genotypes to GSK. “This purchase follows shortly after GlaxoSmithKline expanded their initial scope of work for a multiyear, genotyping services agreement with Illumina, demonstrating their continued uptake of our technology,” said Jay Flatley, Illumina president and CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »